KR20230154498A - Composition for preventing or treating of skin damage by a light irradiation comprising echinochrome A - Google Patents

Abstract

The present invention relates to a composition for preventing or treating skin damage diseases caused by light irradiation containing Echinochrome A as an active ingredient. Echinochrome A has the effect of improving skin epidermal thickness or densifying dermal collagen fibers. It is excellent and reduces transepidermal moisture loss to induce recovery of epidermal skin lesions, so it can be effectively used as a medicine, health functional food, or cosmetic to prevent or treat skin damage diseases caused by light irradiation.

Description

Composition for preventing or treating skin damage by a light irradiation comprising echinochrome A}

The present invention provides a composition for preventing or treating skin damage caused by light irradiation, containing echinochrome A as an active ingredient.

The sun emits light energy with a wide range of wavelengths. Ultraviolet rays (UV) radiation, which has a shorter wavelength than the blue or violet rays of visible light, burns the skin and has harmful health effects. The ozone layer in the stratosphere prevents most harmful ultraviolet rays from reaching the Earth, but as the ozone layer in the stratosphere becomes thinner, the amount of ultraviolet radiation reaching the Earth's surface is increasing.

Ultraviolet rays in sunlight cause photodamage to the skin, adversely affecting the skin's beauty condition and skin health.

Photodamage is a phenomenon that occurs due to a photobiological reaction when the skin is exposed to light. It is divided into acute photodamage that occurs immediately after exposure to light and chronic photodamage that occurs after exposure to light for a long period of time. Examples of chronic photodamage include photoaging or skin cancer, such as pigmentation or roughening of the skin, and examples of acute photodamage include photoburn or pigmentation.

Most photodamage to the skin occurs in the epidermis layer and upper dermis, where ultraviolet rays penetrate, and oxygen free radicals generated by ultraviolet irradiation are closely related to photodamage caused by ultraviolet rays, such as pigmentation, aging, and skin cancer. It is known.

Among ultraviolet rays, ultraviolet B (UVB: 290-320 nm) has the greatest photobiological effect on the human body and is the main cause of photodamage to the skin, while ultraviolet C (UVC: 200-290 nm) has the power to destroy cells. Although it is very strong, its penetration is weak due to its short wavelength, and the energy intensity of ultraviolet A (UVA: 320-400 nm) is about 1/1000 that of UVB, so its effect is minimal.

As a way to prevent photodamage to the skin caused by ultraviolet rays, research on sunscreens is continuously being conducted. Most of the photodamage prevention agents developed to date are in the form of being applied to the skin, and agents that can reduce light absorption by chemically or physically absorbing, dispersing, or reflecting sunlight are used.

Although previously developed sunscreens have the effect of protecting cells by blocking the penetration of ultraviolet rays, they cannot suppress the cell damage at all after ultraviolet rays penetrate the epidermis layer and upper dermis layer, making it impossible to effectively suppress photodamage.

Therefore, there is a need to develop an effective treatment that suppresses photodamage to skin exposed to ultraviolet rays.

1. Republic of Korea Patent No. 10-2225792.

The purpose of the present invention is to provide a composition for preventing or treating skin damage caused by light irradiation, containing echinochrome A as an active ingredient.

Another object of the present invention is to provide a cosmetic composition for improving skin photoaging or wrinkles containing echinochrome A as an active ingredient.

Another object of the present invention is to provide a health functional food composition for improving skin photoaging or wrinkles containing echinochrome A as an active ingredient.

Another object of the present invention is to provide a reagent composition for inhibiting the expression of MMP-1 (Matrix metalloproteinase-1) or MMP-2 (matrix metalloproteinase-2) containing echinochrome A as an active ingredient.

In order to achieve the above object, the present invention provides a composition for preventing or treating skin damage caused by light irradiation containing echinochrome A as an active ingredient.

Additionally, the present invention provides a cosmetic composition for improving skin photoaging containing echinochrome A as an active ingredient.

Additionally, the present invention provides a cosmetic composition for improving wrinkles containing echinochrome A as an active ingredient.

In addition, the present invention provides a health functional food composition for improving skin photoaging containing echinochrome A as an active ingredient.

In addition, the present invention provides a health functional food composition for improving wrinkles containing echinochrome A as an active ingredient.

Additionally, the present invention provides a reagent composition for inhibiting the expression of MMP-1 (Matrix metalloproteinase-1) containing echinochrome A as an active ingredient.

Additionally, the present invention provides a reagent composition for inhibiting the expression of matrix metalloproteinase-2 (MMP-2) containing echinochrome A as an active ingredient.

The present invention provides a composition for preventing or treating skin damage caused by light irradiation containing Echinochrome A as an active ingredient. Echinochrome A not only attenuates tissue inflammation and significantly reduces transepidermal water loss, but also reduces collagen It is very effective in preventing or treating skin damage caused by light irradiation by reducing decomposition and inflammatory cell infiltration. Since it is a safe material, it is useful as a medicine for preventing or treating skin damage caused by light irradiation, cosmetics for improving skin photoaging or wrinkles, and health functional foods. It can be used in the form

Figure 1 shows changes in skin physiological function over time in the UV non-treated group, UV treated group, and UV + Echinochrome A (hereinafter referred to as Ech A) treated group.
Figure 2 confirms the results of histological measurement and statistical analysis of epidermal thickness and papillomatosis width and depth in mouse dorsal skin.
Figure 3 confirms the histological observation results of the dorsal skin of the UV untreated group, UV treated group, and UV + Ech A treated group.
Figure 4 confirms the results of statistical analysis of the histological appearance and mast cell number of the dorsal skin.
Figure 5 shows matrix metalloproteinase-1 (hereinafter referred to as MMP-1), matrix metalloproteinase-1 (hereinafter referred to as MMP-2), and tryptase by Ech A treatment. The results of expression of IZ and Kymase were confirmed.

Hereinafter, the present invention will be described in more detail.

While researching a more effective and biosafe treatment method to solve skin damage caused by light irradiation, the present inventor discovered that Echinochrome A, a natural pigment isolated from sea urchins, was used to reduce transdermal water loss in animal models irradiated with UVB. In addition, the present invention was completed as it was confirmed that collagen reduction was reduced and inflammatory response was reduced.

The present invention provides a composition for preventing or treating skin damage caused by light irradiation, containing echinochrome A as an active ingredient.

The skin damage disease caused by light irradiation may be selected from the group consisting of skin aging caused by light irradiation, skin pigmentation, wrinkles, psoriasis, and eczema, but is not limited thereto.

The light irradiation may occur due to UVB exposure.

The echinochrome A inhibits the expression of one or more proteins selected from the group consisting of MMP-1 (Matrix metalloproteinase-1), MMP-2 (matrix metalloproteinase-2), Tryptase, and Chymase. However, it is not limited to this.

In another embodiment of the present invention, the composition may comprise suitable carriers, excipients, disintegrants, sweeteners, coating agents, bulking agents, lubricants, lubricants, flavoring agents, antioxidants, buffers, bacteriostatic agents, diluents, It may further include one or more additives selected from the group consisting of dispersants, surfactants, binders, and lubricants. Specifically, carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, and microcrystalline. Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil can be used. Solid preparations for oral administration include tablets, pills, powders, granules, and capsules. agents, etc., and such solid preparations can be prepared by mixing the composition with at least one or more excipients, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium styrate and talc can also be used. Liquid preparations for oral use include suspensions, oral solutions, emulsions, and syrups. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, etc. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao, laurin, glycerogenatin, etc. can be used. According to one embodiment of the present invention, the composition is intravenous, intraarterial, intraperitoneal, intramuscular, intraarterial, intraperitoneal, intrasternal, transdermal, intranasal, inhalational, topical, rectal, oral, intraocular or intradermal. It can be administered to a subject in a conventional manner via any route. The dosage of the active ingredient according to the present invention may vary depending on the subject's condition and weight, type and degree of disease, drug form, administration route and period, and may be appropriately selected by a person skilled in the art, and the daily dosage is 0.01 mg. /kg to 200 mg/kg, preferably 0.1 mg/kg to 200 mg/kg, more preferably 0.1 mg/kg to 100 mg/kg. Administration may be administered once a day or divided into several administrations, and the scope of the present invention is not limited thereby.

Additionally, the present invention provides a cosmetic composition for improving skin photoaging or wrinkles containing echinochrome A as an active ingredient.

The echinochrome A can reduce trans epidermal water loss (TEWL).

The echinochrome A can prevent dermal collagen degeneration or mast cell invasion.

The Echinochrome A is selected from the group consisting of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansers, oils, powder foundations, emulsion foundations, wax foundations and sprays. It may have a dosage form, but is not limited thereto.

When the composition of the present invention is a cosmetic composition, the cosmetic composition may include conventional auxiliaries such as stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers in addition to the active ingredients. Additionally, the cosmetic composition may additionally contain a skin absorption accelerator to enhance its effect. The formulation of the cosmetic composition may be prepared in any formulation commonly prepared in the art. For example, the cosmetic composition may be used as lotion, skin, toner, essence, sunscreen, makeup base, powder, pack, ointment, patch, It can be formulated into sticks, shampoos, rinses, makeup removers, and detergents, but it is not limited thereto. Additionally, when the formulation is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide can be used as carrier ingredients. there is. In addition, when the formulation is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder can be used as the carrier ingredient. In particular, when the formulation is a spray, chlorofluorohydrocarbon, propane/ May contain propellants such as butane or dimethyl ether. Additionally, when the formulation is a solution or emulsion, a solvent, solubilizing agent, or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1, These include 3-butyl glycol oil, fatty esters of glycerol, fatty acid esters of polyethylene glycol or sorbitan. In addition, when the formulation is a suspension, the carrier ingredients include water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, and microcrystalline Cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used.

In addition, the present invention provides a health functional food composition for improving skin photoaging or wrinkles containing echinochrome A as an active ingredient.

The composition may be characterized as an inner beauty food.

The health functional food includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavors, colorants and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, It may contain organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, it may contain pulp for the production of natural fruit juice, synthetic fruit juice, and vegetable drinks. These ingredients can be used independently or in combination. In addition, the health functional food composition may be in the form of any one of meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, gum, ice cream, soup, beverages, tea, functional water, drink, alcohol, and vitamin complex. It can be. In addition, the above-mentioned health functional food may additionally contain food additives, and its suitability as a “food additive” is determined according to the general provisions and general test methods of the Food Additives Code approved by the Food and Drug Administration, unless otherwise specified. Determination is made according to relevant standards and standards. Items listed in the "Food Additives Code" include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as subchromic pigment, licorice extract, crystalline cellulose, cold pigment, and guar gum, L -Mixed preparations such as sodium glutamate preparations, noodle-added alkaline preparations, preservative preparations, and tar color preparations are included. At this time, in the process of manufacturing health functional foods, the content of the active ingredients added to the food can be appropriately adjusted as needed, and is preferably added in an amount of 1 to 90 parts by weight per 100 parts by weight of the food. .

Additionally, the present invention provides a reagent composition for inhibiting the expression of matrix metalloproteinase-1 (MMP-1) or matrix metalloproteinase-2 (MMP-2) containing echinochrome A as an active ingredient.

Hereinafter, to aid understanding of the present invention, it will be described in detail through examples. However, the following examples only illustrate the content of the present invention, and the scope of the present invention is not limited to the following examples. Examples of the present invention are provided to more completely explain the present invention to those with average knowledge in the art.

<Experimental Example 1> Preparation of Echinochrome A

Histochrome ^® (PN002363/02) containing 1 wt% Echinochrome A (hereinafter referred to as Ech A) was obtained from the Pacific Institute of Bioorganic Chemistry, Far East Branch of the Russian Academy of Sciences. The composition of Histochrome was 1wt% Ech A in an isotonic solution of 0.9wt% sodium carbonate and sodium chloride, the concentration was 37.5mM, and it was stored in a refrigerator at 2°C.

<Experimental Example 2> Animal care and use

This study was conducted with the approval of scientific and ethical standards granted by the Animal Care and Use Committee of Inje University Animal Hospital (IU-IACUC, approval number 2020-002). The animals used in the experiment were 6-week-old SKH-1 hairless mice purchased from Orient Bio Laboratory Animals (Daejeon). All mice were housed under a 12-h light/dark cycle at a temperature of 22 ± 2°C and 45 ± 5% humidity and had free access to standard diet and water.

<Experimental Example 3> Experimental design

All mice (n = 20) were assigned to a normal control group (n = 4) and one of two UV radiation groups. The UV radiation group was subdivided into a phosphate-buffered saline (PBS) intraperitoneal injection group (UVB, n = 8) and an Ech A intraperitoneal injection group (UVB + Ech A, n = 8).

<Experimental Example 4> Ultraviolet irradiation

The UV irradiation device was shaped like a rectangular box with a width of 60 cm, a length of 40 cm, and a height of 40 cm, and was manufactured by NSC, Inc. (Hwaseong, Korea). The device was equipped with a TL20W/01RS lamp (Phillips™, Eindhoven, Netherlands), which emits UVB with a narrow peak wavelength of 311 nm. The distance between the UV lamp and the mouse was maintained at 30 cm, and UVB emission was measured with an ILT-1700 research radiometer (International Light Technology™, Boston, MA, USA). Irradiation was performed every two days for eight weeks, with a two-day break after the third irradiation each week. UVB is administered at 1 Minimal Erythema Dose (hereinafter referred to as MED) for the first week and then gradually increased to 2 MED, 3 MED and 4 MED over the next 3 weeks, reaching a plateau at 4 MED at the end of 8 weeks. The amount was increased until.

<Experimental Example 5> 1 MED settings

MED represents the minimum UV radiation dose that can cause erythema on the skin. MED is generally used as a practical indicator to determine the degree of impact of UV irradiation. To set the level of 1 MED, a cloth with a 1 cm diameter hole was used to cover the back skin of the mouse and 60, 80, 100, 120, 140 and 160 mJ were irradiated to six different areas. The UVB radiation dose was calculated to be approximately 1 mJ per second and it took approximately 11 minutes to set up the MED. After 24 hours, it was observed which of the six areas erythema occurred in.

<Experimental Example 6> Intraperitoneal drug injection

Immediately after UVB irradiation, Ech A reagent was injected into the intraperitoneal space in the UVB and UVB + Ech A groups. The UVB group was administered 200 μL of PBS, and the UVB + Ech A group was administered 0.1 mg/kg of Ech A mixed with 200 μL of PBS.

<Experimental Example 7> Clinical observation of skin condition

To check for changes in the condition of the back skin, pictures were taken with a camera and dermoscope (DermLite™ DLCAM, Dermlite, San Juan Capistrano, CA, USA) before the first survey day each week. Mice were imaged under anesthesia by brief inhalation of isoflurane.

<Experimental Example 8> Transepidermal Water Loss (TEWL) measurement

The day after the two-week UV irradiation schedule was completed, transepidermal water loss (TEWL) was measured with a Tewameter™. A measuring probe was placed on the mid-portion of the dorsal skin of a mouse anesthetized by inhaling a low concentration of isoflurane. TEWL values were measured at the plateau of the estimation graph.

<Experimental Example 9> Histological analysis

Two days after the last UV irradiation, all mice were sacrificed using CO ₂ gas and dorsal skin tissue samples were collected. The collected sample was divided into four parts and one of them was fixed in a 4 wt% paraformaldehyde solution at room temperature for 24 hours and then transferred to a 50 wt% ethyl alcohol solution. After 24 hours, samples were fixed in paraffin wax and cut into 4-μm slices. Skin sections were stained with hematoxylin and eosin (H&E), Martian's trichrome, and toluidine blue. Anti-Collagen I antibody, anti-MMP9 antibody, and anti-beta galactosidase antibody and anti-Collagen III polyclonal antibody, anti-MMP1 polyclonal antibody, and Invitrogen™ (Carlsbad) were purchased from Abcam® (Cambridge, UK). Anti-MMP2 monoclonal antibody purchased from , CA, USA). Stained slides were observed and photographed using light microscopes Olympus™ BH2 (Tokyo, Japan) and Tucsen™ Digiretina 16 (Fuzhou, China). The average epidermal thickness was calculated by measuring the distance between the dermoepidermal junction and the top of the granular layer in five different areas of each specimen at a magnification of 200 times using the computer-assisted program Tucsen™ TCapture (Fuzhou, China). Additionally, the width of the papillomatosis was measured as the horizontal distance between the shoulders of the papillomatosis, and the depth was calculated as the shortest distance between the bottom of the basal sulcus and the horizontal line between the shoulders of the papillomatosis. Additionally, the number of mast cells on the slide stained with toluidine brew was calculated as the average value of five randomly selected fields of view at ×100 magnification.

<Experimental Example 10> Western blot

Mouse back skin tissue was incubated in radioimmunoprecipitation assay buffer containing protease and phosphatase inhibitors (50mM Tris-HCl, pH 7.5, 150mM NaCl, 0.5wt% sodium deoxycholate, 1wt% Triton SDS) was dissolved. Protein concentration was analyzed using the Bio-Rad DC protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Lysates were separated by 8–15% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (GE Healthcare, Chicago, IL, USA) at 100 V for 100 min at 4°C. Membranes were blocked with 5% skim milk in TBST (20 mmol/L TrisHCl, pH 7.5, 50 mmol/L NaCl, and 0.1 wt% Tween 20). After blocking, membranes were incubated overnight with primary antibodies diluted 1:1000 in 3% bovine serum albumin (BSA) in TBST. After washing three times for 15 min, the membrane was incubated with horseradish peroxidase inhibitory secondary antibody diluted 1:5000 in 3% BSA for 1 h. Protein bands were visualized using an enhanced chemiluminescence kit (Santa Cruz Biotechnology, Dallas, TX, United States) and then observed with an AI 600 Imager (GE Healthcare, Chicago, IL, USA).

<Example 1> Confirmation of the effect of reducing transepidermal water loss (TEWL) by applying Ech A

To measure the TEWL score, TEWL was measured every two weeks after Ech A treatment on the dorsal skin of mice after the two-week UV irradiation schedule was completed through Tewameter ^® measurement.

As a result, according to Figure 1, there was no significant difference in TEWL at week 2 in any group. From week 4 onwards, a significant increase in TEWL was observed in UVB-irradiated mice. Additionally, according to Figures 1C and 1D, the UVB irradiation only group (UVB) showed a faster rise in TEWL compared to the UVB irradiation + Ech A treatment group (UVB + Ech A) until the end of the experiment (p < 0.05). In addition, according to Figures 1E and 1F, at the end of the experiment at week 8, TEWL was confirmed to be significantly higher in the UVB group compared to the UVB + Ech A group.

These results showed that Ech A reduces moisture loss and maintains skin barrier function.

<Example 2> Histopathological effect on mouse skin epidermis by Ech A treatment

Histopathological examination of the dorsal skin tissue was performed to histologically measure and statistically analyze the epidermal thickness of the back skin and the width and depth of papillomatosis.

As a result, according to Figures 2A and 2B, in the epidermis, the UVB group showed more severe hyperkeratosis, acanthosis, spongiomatosis, and papillomatosis than the UVB + Ech A group. In addition, according to Figures 4C, 4D, and 4E, it was confirmed that the average epidermal thickness, papillomatosis width, and papillomatosis depth were significantly increased in the UVB group compared to the UVB + Ech A group.

These results showed that Ech A treatment significantly improved the condition of UVB-damaged epidermis.

<Example 3> Histopathological effect on mouse skin dermis by Ech A treatment

UV irradiation induced interstitial inflammatory cell infiltration around blood vessels composed of dermal lymphocytes. To evaluate the effect of Ech A on this, hematoxylin and eosin (H&E) staining, Martian's trichrome (M-T) staining, and toluidine blue (T-B) staining were performed.

As a result, according to the H&E staining results in Figure 3, it was confirmed that the UVB group showed much denser inflammatory cell infiltration and epidermal stimulation than the UVB + Ech A group. Additionally, according to the M-T staining results, dermal collagen fibers were diffuse and dense in the UVB+Ech A group, while the UVB group showed a significant decrease in collagen fibers. Additionally, T-B staining results showed a denser infiltration of mast cells in the UVB group than in the UVB+Ech A group.

These results showed that Ech A treatment significantly improved the condition of the dermis damaged by UVB.

<Example 4> Confirmation of decreased skin inflammation and mast cell expression by Ech A treatment

To confirm the number of mast cells, the toluidine-blue stained slide in Example 3 was used and the number of cells was calculated at 5x magnification. In addition, to confirm the effect of Ech A on skin inflammation, MMP, a skin inflammation marker, and tryptase and chymase, markers of mast cells, were used.

As a result, according to Figure 4, it was confirmed that the average number of mast cells was significantly higher in the UVB group than in the UVB + Ech A treatment group. In addition, according to Figure 5, the relative expression of MMP-1, 2, tryptase, and chymase was confirmed to be significantly increased in the UVB group compared to the control group and UVB + Ech A group.

These results showed that Ech A treatment reduced skin inflammation and the expression of mast cells, thereby protecting the skin from photoaging caused by UVB.

The description of the present invention described above is for illustrative purposes, and those skilled in the art will understand that the present invention can be easily modified into other specific forms without changing the technical idea or essential features of the present invention. will be. Therefore, the embodiments described above should be understood in all respects as illustrative and not restrictive.

The scope of the present invention is indicated by the claims described below, and all changes or modified forms derived from the meaning and scope of the claims and their equivalent concepts should be construed as being included in the scope of the present invention.

Claims (11)

A composition for preventing or treating skin damage caused by light irradiation, containing echinochrome A as an active ingredient. The composition according to claim 1, wherein the skin damage disease caused by light irradiation is any one selected from the group consisting of skin aging caused by light irradiation, skin pigmentation, wrinkles, psoriasis, and eczema. The composition according to claim 1, wherein the light irradiation occurs due to UVB exposure. The method of claim 1, wherein the echinochrome A is one or more selected from the group consisting of MMP-1 (Matrix metalloproteinase-1), MMP-2 (matrix metalloproteinase-2), Tryptase, and Chymase. A composition characterized in that it inhibits protein expression. A cosmetic composition for improving skin photoaging or wrinkles containing echinochrome A as an active ingredient. The cosmetic composition according to claim 5, wherein the echinochrome A reduces trans epidermal water loss (TEWL). The cosmetic composition according to claim 5, wherein the echinochrome A prevents dermal collagen degeneration or mast cell invasion. The method of claim 5, wherein the composition is selected from the group consisting of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing agents, oils, powder foundations, emulsion foundations, wax foundations and sprays. A cosmetic composition characterized by having a selected formulation. A health functional food composition for improving skin photoaging or wrinkles containing echinochrome A as an active ingredient. The health functional food composition according to claim 9, wherein the composition is an inner beauty food. A reagent composition for inhibiting the expression of MMP-1 (Matrix metalloproteinase-1) or MMP-2 (matrix metalloproteinase-2) containing echinochrome A as an active ingredient.